NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Nature
of Business
Ethema
Health Corporation (the “Company”) was incorporated under the laws of the state of Colorado, USA, on April 1, 1993.
Effective April 4, 2017, the Company changed its name to Ethema Health Corporation and prior to that, on May 2012, the Company
had changed its name to GreeneStone Healthcare Corporation from Nova Natural Resources Corporation. As of December 31, 2017, the
Company owned 100% of the outstanding shares of GreeneStone Clinic Muskoka Inc., incorporated in 2010 under the laws of the Province
of Ontario, Canada; Cranberry Cove Holdings Ltd., incorporated on January 9, 2004 under the laws of the Province of Ontario, Canada.
and Seastone Delray Healthcare, LLC, incorporated on May 17, 2016 under the laws of Florida, USA; and Delray Andrews RE, LLC,
incorporated on May 17, 2016 under the laws of Florida, USA.
During
December 2016, the Company obtained a license to operate and provide addiction treatment healthcare services in Florida, USA.
The company commenced operations under this license with effect from January 2017.
On
February 14, 2017, the Company completed a series of transactions (referred to collectively as the “Restructuring Transactions”),
including a Share Purchase Agreement (the “SPA”) whereby the Company acquired 100% of the stock of CCH, which holds
the real estate on which the Company previously operated a rehabilitation clinic (“the Canadian Rehab Clinic”). The
Company entered into an Asset Purchase Agreement (the “APA”) and lease (the “Lease”) whereby the Company
sold all of the Canadian Rehab Clinic business assets and leased the real estate to the buyer. Simultaneously with this transaction,
the Company entered into a Real Estate Purchase agreement and Asset Purchase Agreement whereby the Company purchased the real
estate and business assets of Seastone Delray (the “Florida Purchase”).
The
Share Purchase Agreement
Under
the
SPA,
the Company acquired 100% of the stock of CCH from Leon Developments
Ltd. (“Leon Developments”), a company wholly owned by Shawn E. Leon, who is the President, CEO, and CFO of the Company
(“Mr. Leon”). CCH owns the real estate on which the Canadian Rehab Clinic is located. The total consideration paid
by the Company was CDN$3,517,062, including the assumption of certain liabilities of CCH, which was funded by the assignment to
Leon Developments of certain indebtedness owing to the Company in the amount of CDN$659,918, and the issuance of 60,000,000 shares
of the Company’s common stock to Leon Developments, valued at US$0.0364 per share.
The
Asset Purchase Agreement and Lease
Under
the
APA,
the assets of the Canadian Rehab Clinic were sold by the Company,
through its subsidiary, GreeneStone Clinic Muskoka Inc. (“Muskoka”), to Canadian Addiction Residential Treatment LP
(the “Purchaser”), for a total consideration of CDN$10,000,000, plus an additional performance payment of up to CDN$3,000,000
as a performance payment to be received in 2019 if certain clinic performance metrics are met. The Purchaser completed the sale
with cash proceeds to the Company of CDN$10,000,000, of which CDN$1,500,000 will remain in escrow for up to two years to cover
indemnities given by the Company. The proceeds of the Muskoka clinic asset sale were used to pay down certain tax debts and operational
costs of the Company and to fund the Florida Purchase, mentioned below.
Through
the
APA,
substantially all of the assets of the Canadian Rehab Clinic were
sold, leaving Ethema with only the underlying clinic real estate, which the Company, through its newly acquired subsidiary, CCH
concurrently leased to the Purchaser. The Lease is a triple net lease and provides for a five (5) year primary term with three
(3) five-year renewal options, annual base rent for the first year at CDN$420,000 with annual increases, an option to tenant to
purchase the leased premises and certain first refusal rights.
The
Florida Purchase
Immediately
after closing on the sale of the assets of the Canadian Rehab Clinic, the Company closed on the acquisition of the real estate
assets of Seastone Delray pursuant to certain real estate and asset purchase agreements. The purchase price for the Seastone assets
was US$6,070,000 financed with a purchase money mortgage of US$3,000,000, and US$3,070,000 in cash.
On
November 2, 2017, the Company entered into an Agreement of Purchase and Sale (the “Agreement”) to purchase from AREP
5400 East
Avenue
LLC, a Delaware limited liability company (“Seller”)
certain buildings in
West
Palm Beach, Florida, totaling approximately 80,000
square feet, on which the present tenant operates a substance abuse treatment center (the “Property”). The purchase
price of the Property is $20,530,000, and the Company made nonrefundable down
payments totaling $2,549,955 as of June 30, 2018.
On May 23, 2018, the Company converted the agreement to
purchase AREP 5400 East Avenue LLC. ("the landlord") into a lease agreement with a purchase option of $17,250,000, increasing
August 31, 2018 by $750,000 per month until the purchase option is exercised. The premises is located at 5400, 5402 and 5410 East
Avenue, West Palm Beach, Florida (the "Property"). The lease is for an initial 10 years and provides for two additional
10 year extensions.
The
Company was previously under agreement to purchase the Property from the Landlord. The Property is presently used as a rehabilitation
treatment center. The current tenant at the property, Alternatives in Treatment, LLC, a Florida limited liability company, consented
to the Lease and concurrent with the execution of the Lease entered into a Sublease Agreement with the Company.
ETHEMA
HEALTH CORPORATION
NOTES TO THE
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
1.
|
Nature
of Business (continued)
|
The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles
generally accepted in the United States of America for interim consolidated financial information and Rule 8-03 of Regulation
SX. Accordingly, these unaudited condensed consolidated financial statements do not include all the information and disclosures
required by accounting principles generally accepted in the United States of America for complete financial statements.
All
adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included in these
unaudited condensed consolidated financial statements. Operating results for the three and six month period presented are not
necessarily indicative of the results that may be expected for any other interim period or for the full
year.
The balance sheet at December 31, 2017 has been derived from audited consolidated financial statements. The unaudited condensed
consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto
for the year ended December 31, 2017.
|
2.
|
Summary
of Significant Accounting Policies
|
The
preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted
in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
|
b)
|
Principals
of consolidation and foreign currency translation
|
The
accompanying unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly owned
subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.
The
Company previously owned an operational subsidiary whose functional currency was the Canadian dollar, while the Company’s
reporting currency is the U.S. dollar. The Company recently acquired a property-owning subsidiary, CCH, whose functional currency
is the Canadian dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830,
“Foreign Currency Translation” as follows:
|
●
|
Monetary
assets and liabilities at the rate of exchange in effect at the balance sheet date.
|
|
●
|
Non
monetary assets and equity at historical rates.
|
|
●
|
Revenue
and expense items at the average rate of exchange prevailing during the period.
|
Adjustments
arising from such translations are deferred until realization and are included as a separate component of stockholders’
equity as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in
determining net income (loss) but reported as other comprehensive income (loss).
For
foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange
rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made,
a foreign exchange transaction gain or loss results which is included in determining net income for the period.
The
relevant translation rates are as follows: For the three months ended June 30, 2018; a closing rate of CAD$1.0000 equals US$0.7594
and an average exchange rate of CAD$1.0000 equals US$0.7715.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of Significant Accounting Policies (continued)
|
c)
|
Cash
and cash equivalents
|
The
Company's policy is to disclose bank balances under cash, including bank overdrafts with balances that fluctuate frequently from
being positive to overdrawn and term deposits with a maturity period of three months or less from the date of acquisition.
The
Company has two operating segments from which it derives revenues, i) rental income from leasing of a rehabilitation facility
to third parties and ii) in-patient revenues for rehabilitation services provided to customers. Revenue is recognized as follows:
In
terms of the lease agreement, on a monthly basis as long as the facility is utilized by the tenant
The
customers have been treated and provided with services by the Company; there is clear evidence that an arrangement exists; the
amount of revenue and related costs can be measured reliably; and it is probable that the economic benefits associated with the
transaction will flow to the Company.
The
Company recognizes revenue from the rendering of services when they are earned; specifically, when all of the following conditions
are met:
|
●
|
the
significant risks and rewards of ownership are transferred to customers and the Company retains neither continuing involvement
nor effective control;
|
|
●
|
there is clear evidence that
an arrangement exists;
|
|
●
|
the amount of revenue and
related costs can be measured reliably; and
|
|
●
|
it is probable that the economic
benefits associated with the transaction will flow to the Company.
|
In
particular, the Company recognizes:
|
●
|
Fees
for outpatient counselling, coaching, intervention, psychological assessments and other related services when patients receive
the service; and
|
|
●
|
Fees for inpatient addiction
treatments proportionately over the term of the patient’s treatment.
|
Deferred revenue
represents monies deposited by the patients for future services to be provided by the Company. Such monies will be recognized
into revenue as the patient progresses through their treatment term.
|
e)
|
Recent
accounting pronouncements
|
In
June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based
Payment Accounting.
The
amendments in this Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services
from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on
inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards
vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment
transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing
share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively
provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of
a contract accounted for under Topic 606, Revenue from Contracts with Customers.
The
amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including
interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after
December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but
no earlier than an entity’s adoption date of Topic 606.
The
impact of this ASU on the Company’s financial statements is not expected to be material.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of Significant Accounting Policies (continued)
|
e)
|
Recent
accounting pronouncements (continued)
|
In
July 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements.
The
amendments in this Update provide entities with an additional (and optional) transition method to adopt the new leases standard.
Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect
adjustment to the opening balance of retained earnings in the period of adoption consistent with preparers’ requests.
The
amendments in this Update provide lessors with a practical expedient, by class of underlying asset, to not separate non-lease
components from the associated lease component and, instead, to account for those components as a single component if the non-lease
components otherwise would be accounted for under the new revenue guidance (Topic 606) and both of the following are met: 1. The
timing and pattern of transfer of the non-lease component(s) and associated lease component are the same. 2. The lease component,
if accounted for separately, would be classified as an operating lease.
The
amendments in this Update related to separating components of a contract affect the amendments in Update 2016-02, which are not
yet effective but can be early adopted.
The
Company is currently considering the impact this ASU will have on its financial statements.
Any
new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a
future date are not expected to have a material impact on the financial statements upon adoption.
The Company is exposed
to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure
and concentrations at the balance sheet date, June 30, 2018 and December 31, 2017.
Credit
risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge
an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.
Credit
risk associated with accounts receivable of Seastone of Delray is mitigated as only a percentage of the revenue billed to health
insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst
several health insurance companies located in the US.
In
the opinion of management, credit risk with respect to accounts receivable is assessed as low.
Liquidity
risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity
risk through its working capital deficiency of $10,108,841 and accumulated deficit of $26,498,019. As disclosed in note 4, the
Company will be dependent upon the raising of additional capital in order to implement its business plan. There is no assurance
that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material
adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material
and remains unchanged from the prior year.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of Significant Accounting Policies (continued)
|
f)
|
Financial
instruments (continued)
|
Market
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is
exposed to interest rate risk and currency risk.
Interest
rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in
market interest rates. The Company is exposed to minimal interest rate risk on its bank indebtedness as there is a balance owing
of $768 as of June 30, 2018. This liability is based on floating rates of interest that have been stable during the current reporting
period. In the opinion of management, interest rate risk is assessed as low, not material and remains unchanged from the prior
year.
Currency
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign
exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations
in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian
dollars. Based on the net exposures at June 30, 2018, a 5% depreciation or appreciation of the Canadian dollar against the U.S.
dollar would result in an approximate $5,362 increase or decrease in the Company’s after tax net income from operations.
The Company has not entered into any hedging agreements to mediate this risk. In the opinion of management, currency risk is assessed
as low, material and remains unchanged from the prior year.
Other
price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in
market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors
specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in
the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.
|
g)
|
Derivative
instrument liability
|
The
Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to
determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative
at fair value with changes in fair value recorded in earnings. The Company uses a Black Scholes Option Pricing model to estimate
the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value
of these derivatives during each reporting period are included in the statements of operations. Inputs into the Black Scholes
Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest
rate and the estimated life of the financial instruments being fair valued.
If the conversion
feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion
and Other Options” for consideration of any beneficial conversion feature.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
3.
|
Restatement
of prior period results
|
The
Company finalized the Purchase Price allocation for the acquisition of the assets of Seastone and CCH during December 2017. This
resulted in the retroactive restatement of the statement of the unaudited condensed consolidated statement of operations and the
unaudited condensed consolidated statement of cash flows for the three and six months ended June 30, 2017.
The
value of the assets acquired were adjusted in line with valuations received and the corresponding depreciation charge was adjusted
accordingly.
This
resulted in an increase in other expense of $1,146,600 and $4,701,415 for the three months and six months ended June 30, 2017,
respectively, on the transfer of assets between parties under common control and a net reduction in the associated depreciation
charge of $51,442 and $74,912 for the three months and six months ended June 30, 2017, respectively.
A
further adjustment was made to other income, which was reduced by $62,960 and $94,940, for the three months and six months ended
June 30, 2017, respectively, to modify the Company’s estimate of deferred purchase price consideration due on the disposal
of Muskoka.
The
reconciliation of the unaudited condensed consolidated statement of operations for the three months ended June 30, 2017 is as
follows:
ETHEMA HEALTH CORPORATION
(Formerly known as Greenestone Healthcare Corporation)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Three months
ended June 20, 2017 As previously reported
|
|
Adjustments
|
|
Three
months ended
June 30, 2017
As Restated
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
402,220
|
|
|
|
|
|
|
$
|
402,220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
57,905
|
|
|
|
|
|
|
|
57,905
|
|
Professional fees
|
|
|
66,403
|
|
|
|
|
|
|
|
66,403
|
|
Salaries and wages
|
|
|
173,451
|
|
|
|
|
|
|
|
173,451
|
|
Depreciation and amortization
|
|
|
125,340
|
|
|
|
(51,442
|
)
|
|
|
73,898
|
|
Total operating expenses
|
|
|
423,099
|
|
|
|
(51,442
|
)
|
|
|
371,657
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) gain
|
|
|
(20,879
|
)
|
|
|
51,442
|
|
|
|
30,563
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
63,960
|
|
|
|
(62,960
|
)
|
|
|
1,000
|
|
Other expense
|
|
|
1,127,335
|
|
|
|
(1,146,600
|
)
|
|
|
(19,265
|
)
|
Interest expense
|
|
|
(93,603
|
)
|
|
|
|
|
|
|
(93,603
|
)
|
Debt discount
|
|
|
(241,666
|
)
|
|
|
|
|
|
|
(241,666
|
)
|
Derivative liability movement
|
|
|
167,580
|
|
|
|
|
|
|
|
167,580
|
|
Foreign exchange movements
|
|
|
(6,438
|
)
|
|
|
|
|
|
|
(6,438
|
)
|
Net loss before taxation from continuing operations
|
|
|
996,289
|
|
|
|
(1,158,118
|
)
|
|
|
(161,829
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net loss from continuing operations
|
|
|
996,289
|
|
|
|
(1,158,118
|
)
|
|
|
(161,829
|
)
|
Net loss from discontinued operations, net of tax
|
|
|
(141,177
|
)
|
|
|
|
|
|
|
(141,177
|
)
|
Net income (loss)
|
|
|
855,112
|
|
|
|
(1,158,118
|
)
|
|
|
(303,006
|
)
|
Accumulated other comprehensive gain
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
154,255
|
|
|
|
|
|
|
|
154,255
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income (loss)
|
|
$
|
1,009,367
|
|
|
$
|
(1,158,117
|
)
|
|
$
|
(148,751
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per common share from continuing operations
|
|
$
|
0.01
|
|
|
$
|
(0.01
|
)
|
|
$
|
(0.00
|
)
|
Basic loss per share from discontinued operations
|
|
$
|
(0.00
|
)
|
|
$
|
—
|
|
|
$
|
(0.00
|
)
|
Basic income per common share
|
|
$
|
0.01
|
|
|
$
|
0.01
|
|
|
$
|
0.00
|
|
Diluted income per share from discontinued operations
|
|
$
|
(0.00
|
)
|
|
$
|
—
|
|
|
$
|
(0.00
|
)
|
Diluted income (loss) per common share
|
|
$
|
0.01
|
|
|
$
|
(0.01
|
)
|
|
$
|
(0.00
|
)
|
Weighted average common shares outstanding - Basic
|
|
|
108,772,921
|
|
|
|
108,772,921
|
|
|
|
108,772,921
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
3.
|
Restatement
of prior period results (continued)
|
The
reconciliation of the unaudited condensed consolidated statement of operations for the six months ended June 30, 2017 is as follows:
ETHEMA HEALTH CORPORATION
(Formerly known as Greenestone Healthcare Corporation)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Six months
ended June 30, 2017 As previously reported
|
|
Adjustments
|
|
Six months ended June 30, 2017
As Restated
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
724,730
|
|
|
|
|
|
|
$
|
724,730
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
408,442
|
|
|
|
|
|
|
|
408,442
|
|
Professional fees
|
|
|
399,204
|
|
|
|
|
|
|
|
399,204
|
|
Salaries and wages
|
|
|
382,695
|
|
|
|
|
|
|
|
382,695
|
|
Depreciation and amortization
|
|
|
182,406
|
|
|
|
(74,912
|
)
|
|
|
107,494
|
|
Total operating expenses
|
|
|
1,372,747
|
|
|
|
(74,912
|
)
|
|
|
1,297,835
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(648,017
|
)
|
|
|
74,912
|
|
|
|
(573,105
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
568,309
|
|
|
|
(94,940
|
)
|
|
|
473,369
|
|
Other expense
|
|
|
(392,539
|
)
|
|
|
(4,701,415
|
)
|
|
|
(5,093,954
|
)
|
Interest income
|
|
|
32,074
|
|
|
|
|
|
|
|
32,074
|
|
Interest expense
|
|
|
(156,620
|
)
|
|
|
|
|
|
|
(156,620
|
)
|
Debt discount
|
|
|
(429,325
|
)
|
|
|
|
|
|
|
(429,325
|
)
|
Derivative liability movement
|
|
|
94,532
|
|
|
|
|
|
|
|
94,532
|
|
Foreign exchange movements
|
|
|
(164,347
|
)
|
|
|
|
|
|
|
(164,347
|
)
|
Net loss before taxation from continuing operations
|
|
|
(1,095,933
|
)
|
|
|
(4,721,443
|
)
|
|
|
(5,817,376
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net loss from continuing operations
|
|
|
(1,095,933
|
)
|
|
|
(4,721,443
|
)
|
|
|
(5,817,376
|
)
|
Net income from discontinued operations, net of tax
|
|
|
7,412,643
|
|
|
|
|
|
|
|
7,412,643
|
|
Net income
|
|
|
6,316,710
|
|
|
|
(4,721,443
|
)
|
|
|
1,595,267
|
|
Accumulated other comprehensive gain
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
|
(36,692
|
)
|
|
|
|
|
|
|
(36,692
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
$
|
6,280,018
|
|
|
$
|
(4,721,443
|
)
|
|
$
|
1,558,575
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic loss per common share from continuing operations
|
|
$
|
(0.01
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.06
|
)
|
Basic income per share from discontinued operations
|
|
$
|
0.08
|
|
|
$
|
—
|
|
|
$
|
0.08
|
|
Basic income per common share
|
|
$
|
0.07
|
|
|
$
|
(0.05
|
)
|
|
$
|
0.02
|
|
Diluted loss per common share from continuing operations
|
|
$
|
(0.01
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.06
|
)
|
Diluted income per share from discontinued operations
|
|
$
|
0.07
|
|
|
$
|
—
|
|
|
$
|
0.07
|
|
Diluted income per common share
|
|
$
|
0.06
|
|
|
$
|
(0.04
|
)
|
|
$
|
0.01
|
|
Weighted average common shares outstanding - Basic
|
|
|
93,838,855
|
|
|
|
93,838,855
|
|
|
|
93,838,855
|
|
Weighted average common shares outstanding - Diluted
|
|
|
104,974,243
|
|
|
|
104,974,243
|
|
|
|
104,974,243
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
3.
|
Restatement
of prior period results (continued)
|
The reconciliation
of the unadjusted condensed consolidated statement of cash flows for the six months ended June 30, 2017 is as follows:
ETHEMA HEALTH CORPORATION
(Formerly known as Greenestone Healthcare Corporation)
|
|
June 30, 2017
As
previously reported
|
|
Adjustments
|
|
June
30, 2017
Adjusted Total
|
Operating
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
|
6,316,710
|
|
|
$
|
(4,721,443
|
)
|
|
$
|
1,595,267
|
|
Net
income from discontinued operations
|
|
|
(7,412,643
|
)
|
|
|
|
|
|
|
(7,412,643
|
)
|
Net
loss from continuing operations
|
|
|
(1,095,933
|
)
|
|
|
(4,721,443
|
)
|
|
|
(5,817,376
|
)
|
Adjustment
to reconcile net loss to net cash (used in) provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
182,406
|
|
|
|
(74,912
|
)
|
|
|
107,494
|
|
Non
cash compensation expense on acquisition of subsidiary
|
|
|
373,274
|
|
|
|
4,701,415
|
|
|
|
5,074,689
|
|
Loss
on mortgage sold
|
|
|
19,265
|
|
|
|
|
|
|
|
19,265
|
|
Non
cash compensation for services
|
|
|
4,000
|
|
|
|
|
|
|
|
4,000
|
|
Other
foreign exchange movements
|
|
|
(27,476
|
)
|
|
|
|
|
|
|
(27,476
|
)
|
Amortization
of debt discount
|
|
|
429,325
|
|
|
|
|
|
|
|
429,325
|
|
Derivative
liability movements
|
|
|
(94,532
|
)
|
|
|
|
|
|
|
(94,532
|
)
|
Provision
against receivable on sale of subsidiary
|
|
|
(446,476
|
)
|
|
|
|
|
|
|
(446,476
|
)
|
Changes
in operating assets and liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(327,351
|
)
|
|
|
|
|
|
|
(327,351
|
)
|
Prepaid
expenses
|
|
|
(6,776
|
)
|
|
|
|
|
|
|
(6,776
|
)
|
Accounts
payable and accrued liabilities
|
|
|
(150,095
|
)
|
|
|
94,940
|
|
|
|
(55,155
|
)
|
Taxes
payable
|
|
|
(2,401,665
|
)
|
|
|
|
|
|
|
(2,401,665
|
)
|
Net
cash used in operating activities - continuing operations
|
|
|
(3,542,034
|
)
|
|
|
—
|
|
|
|
(3,542,034
|
)
|
Net
cash provided by operating activities - discontinued operations
|
|
|
101,033
|
|
|
|
|
|
|
|
101,033
|
|
|
|
|
(3,441,001
|
)
|
|
|
—
|
|
|
|
(3,441,001
|
)
|
Investing
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments
in Seastone
|
|
|
(2,960,000
|
)
|
|
|
|
|
|
|
(2,960,000
|
)
|
Proceeds
from restricted cash
|
|
|
51,362
|
|
|
|
|
|
|
|
51,362
|
|
Purchase
of fixed assets
|
|
|
(8,878
|
)
|
|
|
|
|
|
|
(8,878
|
)
|
Net
cash used in investing activities - continuing operations
|
|
|
(2,917,516
|
)
|
|
|
—
|
|
|
|
(2,917,516
|
)
|
Net
cash provided by investing activities - discontinued operations
|
|
|
6,241,082
|
|
|
|
|
|
|
|
6,241,082
|
|
|
|
|
3,323,566
|
|
|
|
—
|
|
|
|
3,323,566
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
|
|
|
|
|
|
|
|
(Decrease)
Increase in bank overdraft
|
|
|
(36,605
|
)
|
|
|
|
|
|
|
(36,605
|
)
|
Proceeds
from mortgage sold
|
|
|
111,554
|
|
|
|
|
|
|
|
111,554
|
|
Repayment of mortgage
|
|
|
(85,613
|
)
|
|
|
|
|
|
|
(85,613
|
)
|
Proceeds
from convertible notes
|
|
|
294,500
|
|
|
|
|
|
|
|
294,500
|
|
Repayment
of convertible notes
|
|
|
(130,000
|
)
|
|
|
|
|
|
|
(130,000
|
)
|
(Repayment
of) proceeds from related party notes
|
|
|
26,195
|
|
|
|
|
|
|
|
26,195
|
|
Net
cash provided by financing activities
|
|
|
180,031
|
|
|
|
—
|
|
|
|
180,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect
of exchange rate on cash
|
|
|
(36,692
|
)
|
|
|
|
|
|
|
(36,692
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
change in cash
|
|
|
25,904
|
|
|
|
|
|
|
|
25,904
|
|
Beginning
cash balance
|
|
|
4,779
|
|
|
|
|
|
|
|
4,779
|
|
Ending
cash balance
|
|
$
|
30,683
|
|
|
$
|
—
|
|
|
$
|
30,683
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The
Company’s unaudited condensed consolidated financial statements have been prepared in accordance with US GAAP applicable
to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal
course of business. As of June 30, 2018, the Company has a working capital deficiency of $10,108,841 and accumulated deficit of
$26,498,019. Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures
over the next 12 months. Accordingly, the Company will be dependent upon the raising of additional capital through placement of
common shares, and/or debt financing in order to implement its business plan, and, or generating sufficient revenue in excess
of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity,
stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders
of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject
to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through
arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical
areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future
financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial
condition. These unaudited condensed consolidated financial statements do not include any adjustments to the amounts and classifications
of assets and liabilities that might be necessary should the Company be unable to continue operations.
The
ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common
stock or obtaining debt financing and attaining future profitable operations. Management's plans include selling its equity securities
and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company
will be successful in these efforts.
5. Discontinued
Operations
On
February 14, 2017, the Company completed a series of transactions, including an APA whereby the Company sold certain of
the Canadian Rehab Clinic assets. The assets disposed of business represented substantially all of the operating assets of
the Canadian Rehab Clinic and has been disclosed as a discontinued operation for comparative purposes as of June 30, 2017.
And for the three and six months ended June 30, 2017.
The Statement
of operations for discontinued operations at June 30, 2017 is as follows:
|
|
Three months ended June 30, 2017
|
|
Six months ended June 30,
2017
|
|
|
|
|
|
Revenues
|
|
$
|
(112
|
)
|
|
$
|
232,040
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
—
|
|
|
|
4,196
|
|
General and administrative
|
|
|
31,330
|
|
|
|
118,706
|
|
Professional fees
|
|
|
33,466
|
|
|
|
32,818
|
|
Rent
|
|
|
2,975
|
|
|
|
47,493
|
|
Salaries and wages
|
|
|
(31,913
|
)
|
|
|
201,723
|
|
Total operating expenses
|
|
|
35,858
|
|
|
|
404,936
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
(35,970
|
)
|
|
|
(172,896
|
)
|
|
|
|
|
|
|
|
|
|
Other (Expense) Income
|
|
|
|
|
|
|
|
|
Other expense
|
|
|
(204
|
)
|
|
|
(993
|
)
|
Foreign exchange movements
|
|
|
(105,003
|
)
|
|
|
91,704
|
|
Net (loss) income before taxation
|
|
|
(141,177
|
)
|
|
|
(82,185
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
Net (loss) income from discontinued operations
|
|
$
|
(141,177
|
)
|
|
$
|
(82,185
|
)
|
|
|
|
|
|
|
|
|
|
Gain on disposal of business
|
|
|
—
|
|
|
|
7,494,828
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(141,177
|
)
|
|
$
|
7,412,643
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
6.
|
Deposit
on Real Estate
|
On
November 2, 2017, the Company entered into an Agreement to purchase from AREP 5400 East
Avenue
LLC
certain buildings in
West
Palm Beach, Florida, totaling approximately 80,000
square feet, on which the present tenant operates a substance abuse treatment center. The purchase price of the Property is $20,530,000,
and made a series of nonrefundable down payments totaling $2,549,955 as of June 30, 2018.
On May 23, 2018, the Company converted the agreement to
purchase AREP 5400 East Avenue LLC. ("the landlord") into a lease agreement with a purchase option of $17,250,000, increasing
August 31, 2018 by $750,000 per month until the purchase option is exercised. The premises is located at 5400, 5402 and 5410 East
Avenue, West Palm Beach, Florida (the "Property"). The lease is for an initial 10 years and provides for two additional
10 year extensions.
The
Company was previously under agreement to purchase the Property from the Landlord. The Property is presently used as a rehabilitation
treatment center. The current tenant at the property, Alternatives in Treatment, LLC, a Florida limited liability company, consented
to the Lease and concurrent with the execution of the Lease entered into a Sublease Agreement with the Company.
|
7.
|
Due
from sale of subsidiary
|
On
February 14, 2017, the Company sold its Canadian Rehab Clinic for gross proceeds of CDN$10,000,000, of which CDN$1,500,000 (US$1,155,900)
had been retained in an escrow account for a period of up to two years in order to guarantee the warranties provided by the Company
in terms of the APA. During the six months ended June 30, 2018, CDN960,000 of the escrow was released to the Company, with an
additional CDN$540,000 still outstanding.
|
8.
|
Property,
plant and equipment
|
Property,
plant and equipment consists of the following:
|
|
June 30, 2018
|
|
December 31, 2017
|
|
|
Cost
|
|
Amortization and Impairment
|
|
Net book value
|
|
Net book value
|
|
|
|
|
|
|
|
|
|
Land
|
|
$
|
2,917,204
|
|
|
$
|
—
|
|
|
$
|
2,917,204
|
|
|
$
|
2,925,305
|
|
Buildings
|
|
|
5,928,619
|
|
|
|
(313,033
|
)
|
|
|
5,615,586
|
|
|
|
5,840,268
|
|
Furniture and fixtures
|
|
|
115,750
|
|
|
|
(34,320
|
)
|
|
|
81,430
|
|
|
|
72,047
|
|
Leasehold improvements
|
|
|
307,319
|
|
|
|
(11,891
|
)
|
|
|
295,428
|
|
|
|
316,238
|
|
|
|
$
|
9,268,892
|
|
|
$
|
(359,244
|
)
|
|
$
|
8,909,648
|
|
|
$
|
9,153,858
|
|
Depreciation
expense for the three months ended June 30, 2018 and 2017 was $68,041 and $73,898, respectively, and depreciation expense for
the six months ended June 30, 2018 and 2017 was $136,456 and $107,494, respectively.
The
taxes payable consist of:
|
●
|
A
payroll tax liability of $144,638 (CDN$190,459) in Greenestone Muskoka which is being
paid off in instalments.
|
|
●
|
The
Company has assets and operates businesses in Canada and is required to disclose these
operations to the US taxation authorities, the requisite disclosure has not been made.
Management has reserved the maximum penalty due to the IRS in terms of non-disclosure.
The Company is taking steps to comply with US disclosure requirements, and has established a provision in the amount
of $250,000.
|
|
|
June 30,
2018
|
|
December 31, 2017
|
|
|
|
|
|
Payroll taxes
|
|
$
|
144,638
|
|
|
$
|
155,894
|
|
US penalties due
|
|
|
250,000
|
|
|
|
250,000
|
|
Income tax payable
|
|
|
269,940
|
|
|
|
283,346
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
664,578
|
|
|
$
|
689,240
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
10.
|
Short-term
Convertible Notes
|
The short-term convertible
notes consist of the following:
|
Interest
rate
|
|
Maturity date
|
|
Principal
|
|
Interest
|
|
Debt Discount
|
|
June 30,
2018
|
|
December
31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leonite Investments LLC
|
8.5%
|
|
December 1, 2018
|
|
$ 1,650,000
|
|
$ 10,174
|
|
$ (696,164)
|
|
$ 964,010
|
|
$ 138,502
|
|
6.5%
|
|
On Demand
|
|
165,000
|
|
6,008
|
|
-
|
|
$ 171,008
|
|
-
|
|
8.5%
|
|
On Demand
|
|
605,000
|
|
18,772
|
|
-
|
|
$ 623,772
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Power Up Lending Group Ltd
|
12.0%
|
|
August 15, 2018
|
|
-
|
|
-
|
|
-
|
|
-
|
|
21,951
|
|
12.0%
|
|
December 30, 2018
|
|
153,000
|
|
5,684
|
|
(94,591)
|
|
64,093
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series N Convertible notes
|
6.0%
|
|
November 6 to November 30, 2018
|
|
1,400,000
|
|
4,775
|
|
(1,002,289)
|
|
402,486
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,973,000
|
|
$ 45,413
|
|
$ (1,793,044)
|
|
$ 2,225,369
|
|
$ 160,453
|
Leonite
Capital, LLC
On
December 1, 2017, the Company closed on a private offering to raise US $1,500,000 in capital. The Company issued one senior secured
convertible promissory note with a principal amount of US $1,650,000 to Leonite Capital, LLC. The Note bears interest at the rate
of 6.5% per annum. The initial draw under the Note was $300,000 with a $150,000 original issue discount for a total of $450,000.
The Company issued 1,650,000 shares of the Company’s common stock as a commitment fee and paid $20,000 towards the lenders
legal fees. The Note’s initial maturity date is June 1, 2018. During the term of the Note the Company and the Subsidiaries
will be obligated to make monthly payment of accrued and unpaid interest. The Note contains Company and Subsidiary representations
and warranties, covenants, events of default, and registration rights.
The
Note provided that the parties use reasonable best efforts to close on the remaining $1,200,000 of availability under the Note
by January 1, 2018. As a condition to the closing of the Balance Tranche, the parties must finalize and enter into additional
agreements related to the Private Offering, including, but not limited to, (i) a Securities Purchase Agreement; (ii) a Warrant
Agreement under which the Investor will have the right to purchase up to 27,500,000 shares of the Company’ common stock
for $0.10 per share, subject to adjustment, for a period of five years; (iii) a Securities Pledge Agreement under which the Company
and the Subsidiaries will grant the lender a blanket lien on their assets, and the Company will pledge its equity ownership in
the Subsidiaries. Upon the closing of the Balance Tranche the maturity date of the Note will become December 1, 2018.
On
December 29, 2017, effective as of December 1, 2017, the Company and the Subsidiaries entered into an Amended and Restated Senior
Secured Convertible Promissory Note, which note amends and restates the Note to (a) extend the maturity date to December 1, 2018;
(b) remove CCH, as an obligor; (c) increase the interest rate by 2.00% per annum, to 8.5% per annum; and (d) issue an additional
250,000 shares of the Company’s common stock to the Investor. In connection with the execution of the amendment, the parties
entered into (i) a Securities Purchase Agreement; (ii) a Warrant Agreement under which the Investor will have the right to purchase
up to 27,500,000 shares of the Company’ common stock for $0.10 per share, subject to adjustment, for a period of five years;
(iii) a Security and Pledge Agreement and a General Security Agreement under which the Company and the Subsidiaries will grant
the Investor a blanket lien on their assets, and the Company will pledge its equity ownership in the Subsidiaries; and (iv) a
First Amendment to the, effective January 2, 2018.
At
the execution of the Note, the Investor funded an initial tranche of $300,000. Thereafter the Investor funded a second tranche
of $156,136. Upon the execution of the A&R Note the Investor funded a third tranche of $100,000. Upon the execution of the
First Amendment the Investor funded a final tranche of $850,000, with the remaining $43,764 of availability under the A&R
Note, as amended, serving as a holdback pursuant to the terms of the First Amendment.
Amounts
under the Note are convertible, at the Investors request, into shares of the Company’s common stock at an initial price
of $0.06 per share, subject to adjustment.
On
March 12, 2018, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $330,000, including an Original Issue Discount of $30,000, for net proceeds of $300,000.
The note has a maturity date of March 19, 2018. The outstanding principal amount of the note is convertible at any time and from
time to time at the election of the purchaser following the issue date into shares of the Company’s common stock at a conversion
price equal to $0.06 per share subject to price protection and anti-dilution protection. In conjunction with this note the Company
issued warrants to purchase 5,500,000 shares of common stock at an exercise price of $0.10 per share.
In
Conjunction with this note the Company issued 330,000 shares as a commitment fee at a price of $0.06 per share.
The
note was repaid during March 2018.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
10.
|
Short-term
Convertible Notes (continued)
|
Leonite
Capital, LLC (continued)
On
March 29, 2018, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $165,000, including an Original Issue Discount of $15,000, for net proceeds of $150,000.
The note has a maturity date of April 28, 2018. The outstanding principal amount of the note is convertible at any time and from
time to time at the election of the purchaser following the issue date into shares of the Company’s common stock at a conversion
price equal to $0.06 per share subject to price protection and anti-dilution protection.
In
Conjunction with this note the Company paid a commitment fee of $11,550 settled through the issue of 165,000 shares at a price
of $0.07 per share.
On
April 17, 2018, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $605,000, including an Original Issue Discount of $55,000, for net proceeds of $550,000.
The note had a maturity date of May 8, 2018. The outstanding principal amount of the note is convertible at any time and from
time to time at the election of the purchaser following the issue date into shares of the Company’s common stock at a conversion
price equal to $0.06 per share subject to price protection and anti-dilution protection.
The
Company also issued a further 605,000 shares of common stock to Leonite as a commitment fee, valued at $42,350 at grant date,
and a further 10,083,333 warrants to purchase shares of common stock at an initial exercise price of $0.10 per share, subject
to anti-dilution and price protection.
Power
Up Lending Group LTD
On
November 6, 2017, the Company, entered into a Securities Purchase Agreement with Power Up Lending Group Ltd., pursuant to which
the Company issued to the Purchaser a Convertible Promissory Note in the aggregate principal amount of $103,000. The Note has
a maturity date of August 15, 2018 and bears interest at the at the rate of twelve percent per annum from the date on which the
Note is issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise.
The Company shall have the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible
at any time and from time to time at the election of the Purchaser during the period beginning on the date that is 180 days following
the issue date into shares of the Company’s common stock at a conversion price equal to 61% of the average lowest closing
bid price of the Company’s common stock for the ten trading days prior to conversion.
On
May 5, 2018, the aggregate principal outstanding of $103,000 together with interest and penalty interest thereon, was settled
for gross proceeds of $141,824.
On
March 9,2018, the Company, entered into a Securities Purchase Agreement with Power Up Lending Group Ltd., pursuant to which the
Company issued to the Purchaser a Convertible Promissory Note in the aggregate principal amount of $153,000. The Note has a maturity
date of December 30, 2018 and bears interest at the at the rate of twelve percent per annum from the date on which the Note is
issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company
has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time
and from time to time at the election of the Purchaser during the period beginning on the date that is 180 days following the
issue date into shares of the Company’s common stock at a conversion price equal to 61% of the average lowest closing bid
price of the Company’s common stock for the ten trading days prior to conversion.
Series
N Convertible Notes
On
May 31, 2018, The Company closed a private offering (the “
Private Offering
”) in which it raised $1,450,000
in capital from 4 accredited investors through the issuance to the investors of the Company’s Series N Convertible Notes,
in the total original principal amount of $1,400,000, which Notes are convertible into the Company’s common stock at a conversion
price of $0.08 per share (the “
Notes
”) together with Warrants to purchase up to a total of 17,500,000 shares
of the Company’s common stock at an exercise price of $0.12 per share the. Both the conversion price under the Notes and
the exercise price under the Warrants are subject to standard adjustment mechanisms. The Notes mature on November 30, 2018, and
the Warrants are exercisable until May 31, 2021.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The
loans payable is as follows:
|
Interest rate
|
|
Maturity date
|
|
Principal Outstanding
|
|
Accrued interest
|
|
June 30, 2018
|
|
December 31, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
Cranberry Cove Holdings
|
|
|
|
|
|
|
|
|
|
|
|
Pace Mortgage
|
4.2%
|
|
July 19,2022
|
|
4,087,994
|
|
5,130
|
|
4,093,124
|
|
4,349,374
|
Seastone of Delray
|
|
|
|
|
|
|
|
|
|
|
|
Mortgage
|
5.0%
|
|
February 13, 2020
|
|
2,958,725
|
|
$ 12,328
|
|
2,971,053
|
|
2,986,920
|
|
|
|
|
|
$ 7,046,719
|
|
$ 17,458
|
|
$ 7,064,177
|
|
$ 7,336,294
|
Disclosed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Short-term portion
|
|
|
|
|
|
|
|
|
$ 133,617
|
|
$ 152,402
|
Long-term portion
|
|
|
|
|
|
|
|
|
6,930,560
|
|
7,183,892
|
|
|
|
|
|
|
|
|
|
$ 7,064,177
|
|
$ 7,336,294
|
The aggregate amount
outstanding is payable as follows:
|
|
Amount
|
Within 1 year
|
|
$
|
133,617
|
|
1 to 2 years
|
|
|
3,043,331
|
|
2 to 3 years
|
|
|
109,547
|
|
3 to 4 years
|
|
|
114,196
|
|
Thereafter
|
|
|
3,663,486
|
|
Total
|
|
$
|
7,064,177
|
|
Pace
Mortgage
On
July 19, 2017, CCH, a wholly owned subsidiary closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is
secured by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario (the “Property”).
The loan bears interest at the fixed rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed
the loan and the Company’s chief executive officer and controlling shareholder also has personally guaranteed the Loan.
CCH and the Company have granted the Lender a general security interest in its assets to secure repayment of the Loan. The loan
is amortized with monthly installments of CDN $29,531.
Seastone of Delray
The
Company entered into a Mortgage and Security Agreement with Seastone Delray Healthcare, LLC on February 13, 2017 for the aggregate
principal sum of $3,000,000, bearing interest at the rate of 5% per annum, maturing on February 13, 2020, with monthly repayments
of interest and principal of $15,000. The proceeds of the mortgage of $3,000,000 was used to fund the acquisition of the Seastone
Delray properties.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The
short-term convertible notes, together with certain warrants issued to Leonite Capital LLC, and the short term convertible
notes issued to Labrys Fund LP and Power Up Lending Group, LTD, disclosed in note 10 above, have variable priced conversion
rights with no fixed floor price and will reprice dependent on the share price performance over varying periods of time. This
gives rise to a derivative financial liability, which was initially valued at inception of the convertible notes at
$1,085,837 using a Black-Scholes valuation model.
In addition, warrants
exercisable over 5,500,000 shares of common stock were issued to Leonite Investments, in terms of the Securities Purchase Agreement
and the Warrant Agreement entered into. Refer note 10 above.
The
following assumptions were used in the Black-Scholes valuation model:
|
|
Six months ended
June 30, 2018
|
Calculated stock price
|
|
|
$0.024 to $0.10
|
|
Risk free interest rate
|
|
|
1.6% to 2.73%
|
|
Expected life of convertible notes
|
|
|
1 month to 5 years
|
|
expected volatility of underlying stock
|
|
|
15.4% to 495.3%
|
|
Expected dividend rate
|
|
|
0
|
%
|
The movement in
derivative liability is as follows:
|
Six months ended June 30, 2018
|
|
Year ended December 31, 2017
|
|
|
|
|
Opening balance
|
$ 2,859,832
|
|
$ -
|
Derivative liability arising from convertible notes
|
$ 1,085,837
|
|
$ 1,826,500
|
Fair value adjustment to derivative liability
|
808,951
|
|
1,033,332
|
Closing balance
|
$ 4,754,620
|
|
$ 2,859,832
|
|
13.
|
Related Party Transactions
1816191 Ontario
|
During
the six months ended June 30, 2018, the Company repaid $15,921 to 1816191 Ontario, the Endoscopy clinic.
Shawn
E. Leon
As
of June 30, 2018, and December 31, 2017 the Company had a receivable of $19,265 and $16,080, respectively to Shawn E. Leon, a
director and CEO of the Company. The balances receivable are non-interest bearing and have no fixed repayment terms.
Mr.
Leon was paid management fees of $92,098 during the six months ended June 30, 2018.
Leon
Developments, Ltd.
The
Company acquired CCH from Leon Developments, Ltd., on February 14, 2017. CCH owns the facility utilized by the Canadian Rehab
Clinic which was sold to a third party on February 14, 2017. CCH owed CDN $2,692,512 to Leon Developments. The amount owing to
Leon Developments Ltd., as of June 30, 2018 was $1,542,681.
Cranberry
Cove Holdings Ltd.
The
Company acquired CCH on February 14, 2017. CCH owns the real estate previously utilized by the Canadian Rehab Clinic and now utilized
by the purchaser of the business.
Prior
to the acquisition of CCH, the Company paid rental expense to CCH of $58,925 for the period ended June 30, 2017.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
14.
|
Stockholders’
deficit
|
On
March 29, 2018, the Company issued 165,000 shares of common stock to Leonite Capital, LLC in connection with the closing of
a financing of a Senior Secured Convertible Note. The shares were valued at $11,550, or $0.07 per share on March
29, 2018.
On
April 17, 2018, the Company issued 605,000 shares of common stock to Leonite Capital, LLC in connection with the closing of
a financing of a Senior Secured Convertible Note. The shares were valued at $39,450 on June 30, 2018.
In terms of the convertible
note agreements entered into with Leonite Capital, LLC, disclosed in note 10 above, the Company agreed to issue warrants exercisable
over a total of 15,583,333 shares of common stock at an exercise price of $0.10 per share.
In terms of the Series
N Convertible debt issued to various accredited investors, disclosed in note 10 above, the Company agreed to issue warrants exercisable
over a total of 17,500,000 shares of common stock at an exercise price of $0.12 per share.
The fair value of Warrants
awarded and revalued during the year ended June 30, 2018 were valued at $799,004 using the Black Scholes pricing model utilizing
the following weighted average assumptions:
|
|
Six months ended June 30, 2018
|
|
|
|
Calculated stock price
|
|
|
0.06 TO 0.08
|
|
Risk free interest rate
|
|
|
2.64 TO 2.75%
|
|
Expected life of warrants (years)
|
|
|
3 to 5 years
|
|
expected volatility of underlying stock
|
|
|
198.8 to 495.3%
|
|
Expected dividend rate
|
|
|
0
|
%
|
The
movements in warrants is summarized as follows:
|
|
|
|
|
No. of shares
|
|
Exercise price per share
|
|
Weighted average exercise price
|
|
|
|
|
|
|
|
|
|
|
Outstanding January 1, 2017
|
|
|
|
|
19,637,409
|
|
$0.0033 to $0.03
|
|
$ 0.03
|
Granted
|
|
|
|
|
29,866,666
|
|
$0.03 to $0.10
|
|
0.0945
|
Exercised
|
|
|
|
|
-
|
|
-
|
|
-
|
Outstanding December 31, 2017
|
|
|
|
|
49,504,075
|
|
$0.0033 to $0.10
|
|
0.0690
|
Granted
|
|
|
|
|
33,083,333
|
|
$0.10 to $0.12
|
|
0.11
|
Forfeited/cancelled
|
|
|
|
|
-
|
|
-
|
|
-
|
Exercised
|
|
|
|
|
-
|
|
-
|
|
-
|
Outstanding June 30, 2018
|
|
|
|
|
82,587,408
|
|
$0.0033 to $0.12
|
|
$0.0850
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
14.
|
Stockholders’
deficit (continued)
|
The following table
summarizes information about warrants outstanding at June 30, 2018:
|
Warrants outstanding
|
|
Warrants exercisable
|
Exercise price
|
No. of shares
|
|
Weighted average remaining years
|
|
Weighted average exercise price
|
|
No. of shares
|
|
Weighted average exercise price
|
|
|
|
|
|
|
|
|
|
|
$0.0033
|
300,000
|
|
*
|
|
|
|
300,000
|
|
|
$0.03
|
21,704,075
|
|
1.70
|
|
|
|
21,704,075
|
|
|
$0.10
|
43,083,333
|
|
4.60
|
|
|
|
43,083,333
|
|
|
$0.12
|
17,500,000
|
|
2.90
|
|
|
|
17,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,587,408
|
|
3.45
|
|
$ 0.0850
|
|
82,587,408
|
|
$ 0.0850
|
* In
terms of an agreement entered into with an investor relations company, 300,000 warrants were to be issued as part of the Investor
Relations Agreement. These warrants have not been issued as yet, therefore the warrant terms are uncertain.
All of the warrants
outstanding as of June 30, 2018 are vested. The warrants outstanding as of June 30, 2018 have an intrinsic value of $1,108,205.
Our
board of directors adopted the GreeneStone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our
long- term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder
value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons
for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance
upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors
and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options
under the Plan. We have granted a total of 480,000 options as of June 30, 2018 under the Plan.
No
options were issued, exercised or cancelled for the period under review.
The
following table summarizes information about options outstanding as of June 30, 2018.
|
Options outstanding
|
|
Options exercisable
|
Exercise price
|
No. of shares
|
|
Weighted average remaining years
|
|
Weighted average exercise price
|
|
No. of shares
|
|
Weighted average exercise price
|
|
|
|
|
|
|
|
|
|
|
$0.12
|
480,000
|
|
1.34
|
|
|
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
480,000
|
|
1.34
|
|
$ 0.12
|
|
480,000
|
|
$ 0.12
|
As of June 30,
2018, there was no unrecognized compensation costs related to these options and the intrinsic value of the options is $0.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLDATED FINANCIAL STATEMENTS
The Company has two
reportable operating segments;
|
a.
|
Rental
income from the property owned by Cranberry Cove subsidiary located at 3571 Muskoka Road,
#169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to
disposal on February 14, 2017 and subsequently leased to the purchasers of the business
of the Canadian Rehab Clinic, for a period of 5 years renewable for a further three five-year
periods and with an option to acquire the property at a fixed price.
|
|
b.
|
Rehabilitation
Services provided to customers, during the three months ended March 31, 2018, these services
were provided to customers at our Seastone of Delray business acquired on February 14,
2017. The Rehabilitation services provided by our Canadian Rehab Center for the three
months ended March 31, 2017 are reported under discontinued operations and have not been
reported as part of the Segment Information.
|
The segment operating
results of the reportable segments are disclosed as follows:
|
|
Three months ended June 30, 2018
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
83,031
|
|
|
$
|
(16,337
|
)
|
|
$
|
66,694
|
|
Operating expenses
|
|
|
45,102
|
|
|
|
750,366
|
|
|
|
795,468
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
37,929
|
|
|
|
(766,703
|
)
|
|
|
(728,774
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
—
|
|
|
|
(49
|
)
|
|
|
(49
|
)
|
Interest expense
|
|
|
(42,845
|
)
|
|
|
(133,742
|
)
|
|
|
(176,587
|
)
|
Amortization of debt discount
|
|
|
—
|
|
|
|
(1,339,885
|
)
|
|
|
(1,339,885
|
)
|
Loss on change in fair value of derivative liability
|
|
|
—
|
|
|
|
(796,795
|
)
|
|
|
(796,795
|
)
|
Foreign exchange movements
|
|
|
18,345
|
|
|
|
92,283
|
|
|
|
110,628
|
|
Net income (loss) before taxation from continuing operations
|
|
|
13,429
|
|
|
|
(2,944,891
|
)
|
|
|
(2,931,462
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net income (loss) from continuing operations
|
|
$
|
13,429
|
|
|
$
|
(2,944,891
|
)
|
|
$
|
(2,931,462
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, 2017
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
78,088
|
|
|
$
|
324,132
|
|
|
$
|
402,220
|
|
Operating expenses
|
|
|
54,875
|
|
|
|
316,782
|
|
|
|
371,657
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
23,213
|
|
|
|
7,350
|
|
|
|
30,563
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
—
|
|
|
|
1,000
|
|
|
|
1,000
|
|
Other expense
|
|
|
—
|
|
|
|
(19,265
|
)
|
|
|
(19,265
|
)
|
Interest expense
|
|
|
(61,535
|
)
|
|
|
(32,068
|
)
|
|
|
(93,603
|
)
|
Amortization of debt discount
|
|
|
—
|
|
|
|
(241,666
|
)
|
|
|
(241,666
|
)
|
Loss on change in fair value of derivative liability
|
|
|
—
|
|
|
|
167,580
|
|
|
|
167,580
|
|
Foreign exchange movements
|
|
|
—
|
|
|
|
(6,438
|
)
|
|
|
(6,438
|
)
|
Net loss before taxation from continuing operations
|
|
|
(38,322
|
)
|
|
|
(123,507
|
)
|
|
|
(161,829
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net loss from continuing operations
|
|
$
|
(38,322
|
)
|
|
$
|
(123,507
|
)
|
|
$
|
(161,829
|
)
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
15.
|
Segment
information (continued)
|
The segment operating
results of the reportable segments are disclosed as follows:
|
|
Six months ended June 30, 2018
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
167,143
|
|
|
$
|
12,853
|
|
|
$
|
179,996
|
|
Operating expenses
|
|
|
76,504
|
|
|
|
1,250,811
|
|
|
|
1,327,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
90,639
|
|
|
|
(1,237,958
|
)
|
|
|
(1,147,319
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
(92,895
|
)
|
|
|
(254,143
|
)
|
|
|
(347,038
|
)
|
Amortization of debt discount
|
|
|
—
|
|
|
|
(2,092,834
|
)
|
|
|
(2,092,834
|
)
|
Loss on change in fair value of derivative liability
|
|
|
—
|
|
|
|
(808,951
|
)
|
|
|
(808,951
|
)
|
Foreign exchange movements
|
|
|
47,555
|
|
|
|
200,969
|
|
|
|
248,524
|
|
Net income (loss) before taxation from continuing operations
|
|
|
45,299
|
|
|
|
(4,192,917
|
)
|
|
|
(4,147,618
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net income (loss) from continuing operations
|
|
$
|
45,299
|
|
|
$
|
(4,192,917
|
)
|
|
$
|
(4,147,618
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended June 30, 2017
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
120,125
|
|
|
$
|
604,605
|
|
|
$
|
724,730
|
|
Operating expenses
|
|
|
60,953
|
|
|
|
1,236,882
|
|
|
|
1,297,835
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
59,172
|
|
|
|
(632,277
|
)
|
|
|
(573,105
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
—
|
|
|
|
473,369
|
|
|
|
473,369
|
|
Other expense
|
|
|
(5,074,689
|
)
|
|
|
(19,265
|
)
|
|
|
(5,093,954
|
)
|
Interest income
|
|
|
—
|
|
|
|
32,074
|
|
|
|
32,074
|
|
Interest expense
|
|
|
(98,188
|
)
|
|
|
(58,432
|
)
|
|
|
(156,620
|
)
|
Amortization of debt discount
|
|
|
—
|
|
|
|
(429,325
|
)
|
|
|
(429,325
|
)
|
Loss on change in fair value of derivative liability
|
|
|
—
|
|
|
|
94,532
|
|
|
|
94,532
|
|
Foreign exchange movements
|
|
|
—
|
|
|
|
(164,347
|
)
|
|
|
(164,347
|
)
|
Net loss before taxation from continuing operations
|
|
|
(5,113,705
|
)
|
|
|
(703,671
|
)
|
|
|
(5,817,376
|
)
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Net loss from continuing operations
|
|
$
|
(5,113,705
|
)
|
|
$
|
(703,671
|
)
|
|
$
|
(5,817,376
|
)
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLDATED FINANCIAL STATEMENTS
|
15.
|
Segment
information (continued)
|
The
operating assets and liabilities of the reportable segments at June 30, 2018, are as follows:
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
Purchase of fixed assets
|
|
$
|
30,860
|
|
|
$
|
10,750
|
|
|
$
|
41,610
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
(11,055
|
)
|
|
|
480,068
|
|
|
|
469,013
|
|
Non-current assets
|
|
|
3,002,860
|
|
|
|
9,279,083
|
|
|
|
12,281,943
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
(2,177,320
|
)
|
|
|
(8,400,534
|
)
|
|
|
(10,577,854
|
)
|
Non-current liabilities
|
|
|
(4,016,836
|
)
|
|
|
(2,913,724)
|
|
|
|
(6,930,560
|
)
|
Intercompany balances
|
|
|
(771,823
|
)
|
|
|
771,823
|
|
|
|
—
|
|
Net (liability) asset position
|
|
$
|
(3,974,174
|
)
|
|
$
|
(783,284
|
)
|
|
$
|
(4,757,458
|
)
|
|
16.
|
Net
loss (income) per common share
|
For the three and six
months ended June 30, 2018, the following options, warrants and convertible notes were excluded from the computation of diluted
net loss per share as the results would have been anti-dilutive.
|
|
Three and six months ended June 30, 2018
|
|
Three months ended June 30, 2017
|
|
|
|
|
|
Stock options
|
|
|
480,000
|
|
|
|
480,000
|
|
Warrants to purchase shares of common stock
|
|
|
82,587,408
|
|
|
|
22,004,075
|
|
Convertible notes
|
|
|
43,916,472
|
|
|
|
3,101,093
|
|
|
|
|
126,983,880
|
|
|
|
25,585,168
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLDATED FINANCIAL STATEMENTS
|
16.
|
Net
loss (income) per common share (continued)
|
For the six months
ended June 30, 2017 the computation of basic and diluted earnings per share is as follows:
|
|
Amount
|
|
Number of shares
|
|
Per share amount
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share from continuing operations
|
|
$
|
(5,817,376
|
)
|
|
|
93,838,855
|
|
|
$
|
(0.06
|
)
|
Net income per share from discontinued operations
|
|
|
7,412,643
|
|
|
|
93,838,855
|
|
|
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per share
|
|
|
1,595,267
|
|
|
|
93,838,855
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
|
|
|
—
|
|
|
|
11,135,388
|
|
|
|
|
|
Convertible debt
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share from continuing operations
|
|
|
(5,817,376
|
)
|
|
|
104,974,243
|
|
|
|
(0.06
|
)
|
Net income per share from discontinued operations
|
|
|
7,412,643
|
|
|
|
104,974,243
|
|
|
|
0.07
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,595,267
|
|
|
|
104,974,243
|
|
|
$
|
0.01
|
|
|
17.
|
Commitments
and contingencies
|
|
a.
|
Contingency
related to outstanding penalties
|
The
Company has provided for potential US penalties of $250,000 due to noncompliance with the filing of certain required returns.
The actual liability may be higher due to interest and penalties assessed by these taxing authorities.
The
Company has assumed operating leases for certain vehicles and office equipment.
On
May 23, 2018, the Company entered into a Lease Agreement pursuant to which it leased from the AREP 5400 East Avenue LLP (the “Landlord”),
the premises located at 5400, 5402, and 5410 East Avenue, West Palm Beach, Florida (the “Property”). The Lease has
an initial term of 10 years and provides for 2 additional 10 year extensions. The Company has the option to purchase the property
for proceeds of $17,250,000 by August 31, 2018, plus any landlord funded improvements. The option to purchase increase by $750,000
per calendar month commencing on August 31, 2018. The initial base rental is $146,337 per month, plus any taxes imposed on the
premises or the base rental.
The
future commitment of these operating leases and the property lease are as follows:
|
|
Amount
|
|
|
|
Within 1 year
|
|
$
|
881,012
|
|
1 to 2 years
|
|
|
1,802,872
|
|
2 - 3 years
|
|
|
1,882,422
|
|
3 - 4 years
|
|
|
1,962,242
|
|
5 years and thereafter
|
|
|
12,165,898
|
|
Total
|
|
$
|
18,694,445
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLDATED FINANCIAL STATEMENTS
|
17.
|
Commitments
and contingencies (continued)
|
The
company has two mortgage loans as disclosed in note 11 above. The future commitments under these loans are as follows:
|
|
Amount
|
|
|
|
Within 1 year
|
|
$
|
3,071,861
|
|
1 to 2 years
|
|
|
105,087
|
|
2 - 3 years
|
|
|
109,547
|
|
3 - 4 years
|
|
|
114,196
|
|
5 years and thereafter
|
|
|
3,663,486
|
|
Total
|
|
$
|
7,066,177
|
|
The
Company has principal and interest payment commitments under the Convertible notes disclosed under Note 10 above. Conversion
of these notes are at the option of the investor, if not converted these notes may need to
be repaid.
From
time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes
there are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material
adverse effect on its business or results of operations.
The
Company is not current in its tax filings for tax years 2011 to 2017 as of June 30, 2018.
On
July 31, 2018, the Company, entered into a Securities Purchase Agreement with Power Up Lending Group Ltd., pursuant to which the
Company issued to the Purchaser a Convertible Promissory Note in the aggregate principal amount of $153,000. The Note has a maturity
date of May 15, 2019 and bears interest at the at the rate of nine percent per annum from the date on which the Note is issued
until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has
the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time and
from time to time at the election of the Purchaser during the period beginning on the date that is 180 days following the issue
date into shares of the Company’s common stock at a conversion price equal to 61% of the average lowest closing bid price
of the Company’s common stock for the ten trading days prior to conversion.